SCHEMBL649653

SCHEMBL649653

Cc1cc(O)ccc1/N=C1/NC(=O)/C(=C/c2cnc(N)s2)S1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.49
NPSR1 Q6W5P4 5/20 0.49
RECQL P46063 1/20 0.49
TDP1 Q9NUW8 2/20 0.48
L3MBTL1 Q9Y468 2/20 0.48
MAPK1 P28482 2/20 0.48
POLB P06746 1/20 0.47
HPGD P15428 1/20 0.47
RNASEL Q05823 1/20 0.46
LMNA P02545 2/20 0.45
ALOX15 P16050 1/20 0.45
PTGS2 P35354 1/20 0.45
CFTR P13569 1/20 0.45
PTP4A3 O75365 1/20 0.43
GRK6 P43250 1/20 0.43
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
CDC25A P30304 1/20 0.43
CDC25B P30305 1/20 0.43
SYK P43405 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL649654 1.00 MAPT (0.49) MAPTNPSR1RECQLTDP1L3MBTL1
SCHEMBL649289 0.90 MAPT (0.61) MAPTNPSR1RECQLTDP1L3MBTL1
SCHEMBL649288 0.90 MAPT (0.61) MAPTNPSR1RECQLTDP1L3MBTL1
SCHEMBL13091576 0.90 MAPT (0.51) MAPTNPSR1RECQLTDP1L3MBTL1
SCHEMBL10176401 0.89 MAPT (0.50) MAPTNPSR1RECQLTDP1L3MBTL1
SCHEMBL653880 0.86 MAPT (0.48) MAPTNPSR1RECQLTDP1L3MBTL1
SCHEMBL653879 0.86 MAPT (0.48) MAPTNPSR1RECQLTDP1L3MBTL1
SCHEMBL699030 0.86 MAPT (0.48) MAPTNPSR1RECQLTDP1L3MBTL1
SCHEMBL648800 0.86 MAPT (0.48) MAPTNPSR1RECQLTDP1L3MBTL1
SCHEMBL649588 0.84 MAPT (0.46) MAPTNPSR1RECQLTDP1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2423204-A1 THIAZOLIDINONE DERIVATIVE SBI Biotech Co., Ltd. (JP) 2012-02-29 EP disclosed
US-8119812-B2 Thiazolidinone derivative SBI BIOTECH CO., LTD. (JP) 2012-02-21 US disclosed
US-8119812-B2 Thiazolidinone derivative SBI BIOTECH CO., LTD. (JP) 2012-02-21 US disclosed
US-8119812-B2 Thiazolidinone derivative SBI BIOTECH CO., LTD. (JP) 2012-02-21 US disclosed
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE SBI BIOTECH CO., LTD. (JP) 2011-08-04 US disclosed
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE SBI BIOTECH CO., LTD. (JP) 2011-08-04 US disclosed
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE SBI BIOTECH CO., LTD. (JP) 2011-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE CDC7, CDK17, CDCA2 MAPT 3657/4885NPSR1 4464/4885RECQL 1217/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.